Investors & Media

  • Webcast
    Cowen 39th Annual Health Care Conference
    03/13/19 10:00 am EDT
  • Webcast
    18th Annual Needham Healthcare Conference
    04/09/19 12:50 pm EDT

Company Profile

As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to treat a broad range of diseases including cardiovascular diseases, neurological diseases, infectious diseases, pulmonary diseases and cancer.

To learn more about Ionis follow us on twitter @ionispharma.

Recent Press Releases

More >>
Date Title and Summary
Toggle Summary Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)
Presentations focus on the benefits of treatment with TEGSEDI™ (inotersen) and results show continued efficacy with long-term exposure in the NEURO-TTR open-label extension study BOSTON and CARLSBAD, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , March 7, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Cowen 39 th Annual Health Care Conference on Wednesday, March 13,
Toggle Summary Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
First and only therapy approved for FCS, a serious and rare disease with no approved treatment options BOSTON, Mass. and CARLSBAD, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals,
Toggle Summary Ionis Exceeds 2018 Financial Guidance
Total revenue increased 17% compared to 2017 to $600 million Commercial revenues more than doubled Conference call and webcast today, February 27, 2019, at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Feb. 27, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Upcoming Events

More >>
Date Event Details
Summary Toggle 06/15/19 12:15 pm CEST - 1:45 pm CEST

Bridging The Gap: Translating Genomic Discovery Into Human Therapeutics 


Cvent link:


Bridging the Gap


European Society of Human Genetics Annual Conference 
Swedish Exhibition & Congress Center
Mässans Gata/Korsvägen
412 94 Göteborg, Sweden

  • Registration for the ESHG conference is required
  • First 50 registrants receive a free gift
  • Lunch will be provided


European Society of Human Genetics Annual Conference
Summary Toggle 04/09/19 12:50 pm EDT

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Copyright West LLC. Minimum 15 minutes delayed.

©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.